Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.47 |
| ▸ | CA9 | Q16790 | 14/20 | 0.47 |
| ▸ | CA1 | P00915 | 14/20 | 0.47 |
| ▸ | CA12 | O43570 | 13/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 10/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA6 | P23280 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27855557 | 0.98 | CA2 (0.45) | CA2CA9CA1CA12CA14 | |
| Hydrochlorthiazide SCHEMBL27904509 | 0.86 | CA12 (0.37) | CA2CA9CA1CA12CA14 | |
| Trifluoroacetic Acid SCHEMBL29746653 | 0.84 | CA12 (0.39) | CA2CA9CA1CA12CA14 | |
| SCHEMBL5220679 | 0.77 | HSP90AA1 (0.39) | CA2CA9CA1CA12CA14 | |
| SCHEMBL29579947 | 0.77 | HSP90AA1 (0.39) | HSP90AA1P2RX7 | |
| SCHEMBL4066547 | 0.77 | HSP90AA1 (0.39) | HSP90AA1P2RX7 | |
| SCHEMBL27564370 | 0.77 | HSP90AA1 (0.39) | HSP90AA1P2RX7 | |
| Hydrochloric Acid SCHEMBL27772824 | 0.76 | HSP90AA1 (0.38) | HSP90AA1P2RX7 | |
| SCHEMBL19422050 | 0.74 | HSP90AA1 (0.37) | CA2CA9CA1CA12CA14 | |
| SCHEMBL1148253 | 0.72 | HSP90AA1 (0.35) | HSP90AA1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022138812-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | モジュラス株式会社 | 2022-06-30 | — | — | WO | claimed |
| CN-107207467-A | 2, 4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | 癌症研究科技有限公司 | 2017-09-26 | — | — | CN | claimed |
| CN-111405899-B | Combination of 4-pyrimidine sulfonamide derivatives with SGLT-2 inhibitors for the treatment of endothelin related disorders | 爱杜西亚药品有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-111405899-B | Combination of 4-pyrimidine sulfonamide derivatives with SGLT-2 inhibitors for the treatment of endothelin related disorders | 爱杜西亚药品有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-117946011-A | Crystalline forms of 4-pyrimidine sulfonamide derivatives | 爱杜西亚药品有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117946011-A | Crystalline forms of 4-pyrimidine sulfonamide derivatives | 爱杜西亚药品有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4269415-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | Modulus Discovery, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| US-11787782-B2 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-10-17 | — | — | US | disclosed |
| US-11680058-B2 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-20 | — | — | US | disclosed |
| WO-2022138812-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | モジュラス株式会社 | 2022-06-30 | — | — | WO | disclosed |
| US-11174247-B2 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-16 | — | — | US | disclosed |
| CN-104011054-A | Thieno- and furo-pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LTD | 2014-08-27 | — | — | CN | disclosed |
| CN-101772494-B | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD | 2013-05-15 | — | — | CN | disclosed |
| CN-101772494-B | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD | 2013-05-15 | — | — | CN | disclosed |
| CN-102970868-A | Treatment of cancers having K-RAS mutations | CURIS INC | 2013-03-13 | — | — | CN | disclosed |
| US-8324232-B2 | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-04 | — | — | US | disclosed |
| CN-102186857-A | Thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INT | 2011-09-14 | — | — | CN | disclosed |
| CN-101772494-A | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD | 2010-07-07 | — | — | CN | disclosed |
| CN-101772494-A | 4-pyrimidinesulfamide derivative | ACTELION PHARMACEUTICALS LTD | 2010-07-07 | — | — | CN | disclosed |
| CN-1953975-A | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists | ALMIRALL PRODESFARMA AG (CH) | 2007-04-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680058-B2 | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan | AGTR2, EDNRA, AGTR1 | CA2 667/4885CA9 1738/4885CA1 2981/4885 |
| US-11174247-B2 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | AGTR1, AGTR2, EDNRA | CA2 149/4885CA9 1920/4885CA1 2854/4885 |
| US-11787782-B2 | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | AGTR1, AGTR2, EDNRA | CA2 149/4885CA9 1920/4885CA1 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.